Google
SVRA — SAVARA INC (Healthcare >> Biotechnology)
SVRA FAQ
What is SVRA's ROE?
SAVARA INC reports a Return on Equity (ROE) of -73.55%.
What is SVRA's dividend yield?
SAVARA INC offers a dividend yield of 0.00%.
What is SVRA's Deepscope Quality Score?
Deepscope rates SVRA's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SVRA?
Deepscope's AI Timing Score for SVRA is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SVRA belong to?
SAVARA INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 5.09
Price
-0.21
(-3.96%)
Day Change
|
|
|---|
SVRA, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.09 |
| PBV / Sector |
5.93 / 4.63
|
| Earning Per Share | -0.63 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
7.14 M
|
| Average 1W Daily Value |
8.24 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:43 |
| Symbol | SVRA |
| Name | SAVARA INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 204.93 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,043.08 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1717 Langhorne Newtown Road, Langhorne, PA, United States, 19047
Phone: 512 614 1848
Website: https://www.savarapharma.com
Employees: 70
Sector: Healthcare >> Biotechnology
Description: Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
